We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

38 hedge funds and large institutions have $49.7M invested in F-star Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

9% more funds holding

Funds holding: 35 → 38 (+3)

14% less capital invested

Capital invested by funds: $57.7M → $49.7M (-$8.03M)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
11
Reduced
9
Closed
6
Calls
$2.69M
Puts
–
Net Calls
+$2.69M
Net Calls Change
-$680K

Top Buyers

Rank Fund Capital Flow
1
TA
Tiedemann Advisors
New York
+$6.13M
2
BI
BVF Inc
California
+$2.54M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.18M
4
IBT
International Biotechnology Trust
United Kingdom
+$1.09M
5
Millennium Management
Millennium Management
New York
+$748K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$4.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.1M
3
SFM
Sphera Funds Management
Israel
-$1.27M
4
EI
EAM Investors
California
-$718K
5
Renaissance Technologies
Renaissance Technologies
New York
-$571K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$11.1M +$2.54M +42,700 +26%
TA
2
Tiedemann Advisors
New York
$5.54M +$6.13M +103,012 New
BBA
3
Baker Bros. Advisors
New York
$5.01M – – –
PCM
4
Parsons Capital Management
Rhode Island
$3.79M +$2.97K +50 +0.1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.65M +$1.18M +19,781 +41%
Axa
6
Axa
France
$3.58M +$280K +4,714 +8%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$3.05M -$2.1M -35,297 -38%
MAM
8
Morse Asset Management
Connecticut
$1.82M +$340K +5,719 +18%
SAM
9
Sectoral Asset Management
Quebec, Canada
$1.66M – – –
CWG
10
C WorldWide Group
Denmark
$1.38M -$132K -2,225 -8%
SFM
11
Sphera Funds Management
Israel
$999K -$1.27M -21,277 -53%
IBT
12
International Biotechnology Trust
United Kingdom
$956K +$1.09M +18,250 New
SAM
13
Silvercrest Asset Management
New York
$851K -$149K -2,500 -14%
PCA
14
Private Capital Advisors
Connecticut
$703K – – –
Millennium Management
15
Millennium Management
New York
$676K +$748K +12,573 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$673K – – –
William Blair & Company
17
William Blair & Company
Illinois
$619K +$137K +2,298 +25%
HCM
18
Highbridge Capital Management
New York
$538K – – –
BlackRock
19
BlackRock
New York
$443K +$63.3K +1,064 +15%
CM
20
Crestline Management
Texas
$442K -$448K -7,529 -48%
Morgan Stanley
21
Morgan Stanley
New York
$328K +$65.4K +1,100 +22%
VV
22
Verity & Verity
South Carolina
$289K +$320K +5,384 New
CS
23
Candriam SCA
Luxembourg
$269K +$297K +5,000 New
LF
24
Lee Financial
Texas
$252K – – –
Northern Trust
25
Northern Trust
Illinois
$209K +$49.6K +834 +27%
1
2

FSTX Hedge Fund Activity: Q4 2017 in Review

38 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2017, worth a combined $49.7M — down 14% from $57.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new FSTX positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was Tiedemann Advisors, opening a new position worth an estimated $6.13M. The largest seller was RTW Investments, exiting entirely with an estimated $4.2M sold.

  • 38 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2017, up from 35 in Q3 2017.
  • Funds reported $49.7M of F-star Therapeutics, Inc. Common Stock stock for Q4 2017, down 14% quarter-over-quarter.
  • 9 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2017 and 6 closed out, a net change of +3 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2017 was Tiedemann Advisors, an estimated $6.13M added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2017 was RTW Investments, an estimated $4.2M sold.

Based on aggregated 13F filings for Q4 2017.